BH3 mimetics antagonizing antiapoptotic Bcl-2 family members, such as Bcl-2, Bcl-xL, and Mcl-1, are currently in clinical use or under development for treatment for hematological malignancies, including AML [11]. This evidence concerns the gene MCL1 and acute myeloid leukemia.